Sotevtamab

Phase 2Monoclonal antibody

AAlethia Biotherapeutics

Sotevtamab is one of 67 biologic programs targeting Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

MS Contin

Merck & Co.

Preclinical

1 4

Sotevtamab

AAlethia Biotherapeutics

Phase 2

1 5

ABI-007

Bristol-Myers Squibb

Preclinical

2 6

Active Comparator

Moderna

Preclinical

1 7

LDE225

Novartis

Preclinical

1 8

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 9

Meglitinides

Sanofi

Preclinical

1 10

Chemotherapy Agents

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Not yet recruiting

Pancreatic Cancer

NCT07488884

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

Recruiting·AAlethia Biotherapeutics·Phase 2·NCT06225843·17 enrolled

Pancreatic Cancer1 trial

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Not yet recruiting·IImmunityBio, Inc.·Phase 1·NCT07488884·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sotevtamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sotevtamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sotevtamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alethia Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AAlethia Biotherapeutics

Sotevtamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Colorectal Cancer1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News